Get the Stockscreener App
481.16
1.49%
-7.28
After Hours:
481.27
0.11
+0.02%
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by abrdn plc - MarketBeat
Vertex challenger Sionna prices $191M IPO - BioPharma Dive
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Jennison Associates LLC - MarketBeat
U.S. Capital Wealth Advisors LLC Has $917,000 Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Alliance Wealth Advisors LLC UT Makes New $377,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC's 'Final Trades' - Benzinga
ICER evidence report on Vertex new treatment for acute pain - The Pharma Letter
Concord Wealth Partners Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Focal Segmental Glomerulosclerosis Market Expected to rise, 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara - Barchart
Final Trades: Energy Transfer, Vertex Pharma, UnitedHealth and Axon Enterprise - CNBC
Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings? - Yahoo Finance
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Lockheed Martin Investment Management Co. Sells 1,660 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Hager Investment Management Services LLC Purchases Shares of 5,384 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Cassia Capital Partners LLC Sells 742 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Concord Asset Management LLC VA Purchases 741 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
After Vertex's FDA pain drug win, Algiax pushes ahead with new non-opioid challenger - FirstWord Pharma
Vertex Pharmaceuticals (NASDAQ:VRTX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug - MSN
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller - MSN
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by E. Ohman J or Asset Management AB - MarketBeat
Cullinan Associates Inc. Sells 1,500 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now? - The Motley Fool
Vertex Pharmaceuticals (NASDAQ:VRTX) Shares Gap Up Following Analyst Upgrade - MarketBeat
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges - MSN
Vertex Pharmaceuticals' (VRTX) "Outperform" Rating Reiterated at William Blair - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Lowered to "Equal Weight" Rating by Wells Fargo & Company - MarketBeat
Hantz Financial Services Inc. Has $507,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Asia’s NewCo Model, FDA tipping point, Vertex’s pain drug: a BioCentury podcast - BioCentury
Country Trust Bank Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Earns "Hold" Rating from Needham & Company LLC - MarketBeat
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance Australia
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
VRTX: 3 Genomic Stocks at the Forefront of Precision Medicine - StockNews.com
Vertex Pharmaceuticals Unusual Options Activity - Benzinga
The first shot taken at Medicaid, and Optum’s wellness visit ad - STAT
3 Magnificent Stocks to Buy and Hold Forever - The Motley Fool
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains? - Yahoo Finance
Vertex stock price target raised to $550 at H.C. Wainwright - MSN
FDA Approval of Journavx: High Pricing Challenges Market Penetration, Neutral Impact on Vertex Stock - TipRanks
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval - Markets Insider
Manning & Napier Advisors LLC Sells 5,635 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? - sharewise
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? - sharewise
Lewis Asset Management LLC Acquires Shares of 750 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
A first in 25 years: FDA approves new type of painkiller - The Jerusalem Post
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
DAVENPORT & Co LLC Cuts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Kingswood Wealth Advisors LLC Sells 3,773 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock - Defense World
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain - Seeking Alpha
Scotiabank Boosts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $433.00 - MarketBeat
0.75%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):